Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine versus aprepitant triple antiemetic prophylaxis during multiday cisplatin chemotherapy with pharmacogenetic analysis
ChiCTR2000036826Phase 4Recruiting
- Sponsor
- Ordos Central Hospital
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of olanzapine, aprepitant and cisplatin in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Ordos Central Hospital. Primary endpoint: Total protection rate. Started Apr 2019; status: recruiting.
02
Drugs
olanzapineaprepitantcisplatin
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on ChiCTR2000036826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036826.